Brief: PCI Biotech: Preliminary Confirmation Safety Endpoint Was Reached In Fimachem Phase I Extension Study

PCI Biotech Holding ASA

20/12/2018 07:10

Dec 20 (Reuters) - PCI Biotech Holding ASA  PCIB.OL :
    * ANNOUNCES PRELIMINARY CONFIRMATION OF SAFETY READ-OUT FROM THE FIMACHEM PHASE I EXTENSION
STUDY
IN BILE DUCT CANCER
    * PRELIMINARY CONFIRMATION THAT SAFETY ENDPOINT HAS BEEN REACHED IN PHASE I EXTENSION STUDY
    * FULL FOCUS IS NOW ON INITIATION AND DELIVERY OF PIVOTAL STUDY, WHICH REMAINS ON TRACK TO
START
FIRST HALF 2019

Source text for Eikon:  ID:nGNE3b1sgQ 
Further company coverage:  PCIB.OL 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))